MedTrace Logo

A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.

NCT00144105 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 562

Last updated 2013-11-01

No results posted yet for this study

Summary

Evaluation of safety and efficacy of Tipranavir (TPV) boosted with Ritonavir (RTV) versus an active control arm (Lopinavir / RTV) in antiretroviral (ARV) therapy naïve HIV-1 infected patients

Conditions

  • HIV Infections

Interventions

DRUG

TPV500mg/RTV200mgBID

DRUG

TPV500mg/RTV100mgBID

DRUG

LPV400mg/RTV100mgBID

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim Study Coordinator

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2006-11-30

Countries

  • Argentina
  • Australia
  • Brazil
  • Canada
  • Colombia
  • France
  • Germany
  • Mexico
  • Poland
  • Romania
  • Russia
  • Spain
  • Thailand
  • The Bahamas
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00144105 on ClinicalTrials.gov